Claims for Patent: 6,565,870

Summary for Patent: 6,565,870

Title:	Methods for treating bone tumors
Abstract:	Methods for treating benign bone tumors by local administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin, to alleviate pain associated with the bone tumor and/or to cause necrosis of the tumor.
Inventor(s):	Donovan; Stephen (Capistrano Beach, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	09/561,106
Patent Claims:	1. A method for treating a bone tumor, the method comprising the step of local administration of a neurotoxin to a bone tumor, thereby reducing pain associated with the bone tumor, wherein the local administration is carried out by insertion of a neurotoxin containing implant. 2. The method of claim 1, wherein the neurotoxin is a botulinum toxin. 3. The method of claim 1, wherein the neurotoxin is a botulinum toxin selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 4. The method of claim 1, wherein the neurotoxin is botulinum toxin type A. 5. The method of claim 1, wherein the neurotoxin is made at least in part by a recombinant process. 6. The method of claim 1, wherein the neurotoxin is administered in an amount between about 0.01 U/kg and about 200 U/kg. 7. The method of claim 1, wherein the pain is substantially alleviated for between about 1 month and about 30 months. 8. A method for treating a bone tumor, the method comprising the step of local administration of a botulinum toxin to a bone tumor to a human patient, thereby substantially alleviating pain associated with or arising from the bone tumor, wherein the local administration is carried out by insertion of a botulinum toxin containing implant. 9. The method of claim 8, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F, and G. 10. A method for treating a benign bone tumor, the method comprising the step of local administration of a neurotoxin to a benign bone tumor, thereby causing a reduction in the size of the benign bone tumor, wherein the local administration is carried out by insertion of a neurotoxin containing implant. 11. The method of claim 10, wherein the benign bone tumor is an osteoid osteoma. 12. The method of claim 10, wherein the neurotoxin is a botulinum toxin. 13. The method of claim 10, wherein the diameter of the benign bone tumor is reduced by between about 20% and about 100% subsequent to the local administration of the neurotoxin. 14. A method for treating a benign bone tumor, the method comprising the step of local administration of a therapeutic amount of a botulinum toxin to a benign bone tumor, thereby causing a reduction in the diameter of the benign bone tumor of between about 20% and about 100%, wherein the local administration is carried out by insertion of a botulinum toxin containing implant. 15. A method for improving patient function, the method comprising the step of local administration of a botulinum toxin to a bone tumor, thereby improving patient function as determined by improvement in one or more of the factors of reduced pain, reduced time spent in bed, improved healing, increased ambulation, improved mental health and decreased role limitations, wherein the local administration is carried out by insertion of a botulinum toxin containing implant. 16. A method for treating a bone tumor, the method comprising the step of locally administering botulinum toxin type A to a benign bone tumor, thereby causing a reduction in the size of the benign bone tumor, wherein the local administration is carried out by insertion of a botulinum toxin type A containing implant. 17. A method for treating a bone tumor, the method comprising the step of locally administering botulinum toxin type B to a benign bone tumor, thereby causing a reduction in the size of the benign bone tumor, wherein the local administration is carried out by insertion of a botulinum toxin type B containing implant.

Details for Patent 6,565,870

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2039-02-26